175 related articles for article (PubMed ID: 26640797)
1. Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells.
Ravacci GR; Brentani MM; Tortelli TC; Torrinhas RS; Santos JR; Logullo AF; Waitzberg DL
Biomed Res Int; 2015; 2015():838652. PubMed ID: 26640797
[TBL] [Abstract][Full Text] [Related]
2. α-linolenic acid and docosahexaenoic acid, alone and combined with trastuzumab, reduce HER2-overexpressing breast cancer cell growth but differentially regulate HER2 signaling pathways.
Mason JK; Klaire S; Kharotia S; Wiggins AK; Thompson LU
Lipids Health Dis; 2015 Aug; 14():91. PubMed ID: 26282560
[TBL] [Abstract][Full Text] [Related]
3. Lipid raft disruption by docosahexaenoic acid induces apoptosis in transformed human mammary luminal epithelial cells harboring HER-2 overexpression.
Ravacci GR; Brentani MM; Tortelli T; Torrinhas RS; Saldanha T; Torres EA; Waitzberg DL
J Nutr Biochem; 2013 Mar; 24(3):505-15. PubMed ID: 22749134
[TBL] [Abstract][Full Text] [Related]
4. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
5. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
Baumann J; Wong J; Sun Y; Conklin DS
BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolic acid potentiates HER2-overexpressing SKBR3 breast cancer cell line to induce apoptosis: involvement of AKT/FOXO1 and JAK2/STAT3 pathways.
Aghazadeh S; Yazdanparast R
Apoptosis; 2016 Nov; 21(11):1302-1314. PubMed ID: 27651367
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.
Vazquez-Martin A; Colomer R; Brunet J; Lupu R; Menendez JA
Cell Prolif; 2008 Feb; 41(1):59-85. PubMed ID: 18211286
[TBL] [Abstract][Full Text] [Related]
9. 188Re-HYNIC-trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells.
Luo TY; Cheng PC; Chiang PF; Chuang TW; Yeh CH; Lin WJ
Ann Nucl Med; 2015 Jan; 29(1):52-62. PubMed ID: 25238789
[TBL] [Abstract][Full Text] [Related]
10. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
[TBL] [Abstract][Full Text] [Related]
11. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
12. Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids.
Rodríguez CE; Reidel SI; Bal de Kier Joffé ED; Jasnis MA; Fiszman GL
PLoS One; 2015; 10(9):e0137920. PubMed ID: 26360292
[TBL] [Abstract][Full Text] [Related]
13. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
Blancafort A; Giró-Perafita A; Oliveras G; Palomeras S; Turrado C; Campuzano Ò; Carrión-Salip D; Massaguer A; Brugada R; Palafox M; Gómez-Miragaya J; González-Suárez E; Puig T
PLoS One; 2015; 10(6):e0131241. PubMed ID: 26107737
[TBL] [Abstract][Full Text] [Related]
14. Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer.
Corominas-Faja B; Vellon L; Cuyàs E; Buxó M; Martin-Castillo B; Serra D; García J; Lupu R; Menendez JA
Histol Histopathol; 2017 Jul; 32(7):687-698. PubMed ID: 27714708
[TBL] [Abstract][Full Text] [Related]
15. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
Seoane S; Montero JC; Ocaña A; Pandiella A
J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
[TBL] [Abstract][Full Text] [Related]
16. Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives.
Menendez JA
Biochim Biophys Acta; 2010 Mar; 1801(3):381-91. PubMed ID: 19782152
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
[TBL] [Abstract][Full Text] [Related]
18. Fatty acid synthase inhibition by amentoflavone suppresses HER2/neu (erbB2) oncogene in SKBR3 human breast cancer cells.
Lee JS; Sul JY; Park JB; Lee MS; Cha EY; Song IS; Kim JR; Chang ES
Phytother Res; 2013 May; 27(5):713-20. PubMed ID: 22767439
[TBL] [Abstract][Full Text] [Related]
19. HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss.
Bartel CA; Jackson MW
PLoS One; 2017; 12(5):e0176778. PubMed ID: 28463969
[TBL] [Abstract][Full Text] [Related]
20. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]